- Other markets
- IG services
- Trading platforms
- IG analysis
No data available for this market
BRIEF: For the nine months ended 30 September 2014, Enzon Pharmaceuticals Inc revenues decreased 8% to $24.9M. Net income increased 81% to $23M. Revenues reflect Royalties decrease of 6% to $24.8M, Miscellaneous income decrease of 85% to $93K. Net income reflects General and administrative decrease of 75% to $1.9M (expense), Restructuring charges decrease from $3.8M (expense) to $0K.
* If your stockbroking account is accessible under the same login as your active spread betting or CFD account, you can qualify for our lowest commission rate if you have placed at least one spread bet or CFD trade in the same calendar month as your application. If you apply for stockbroking in the month following a trade in an existing account you will not receive this rate during your first month where both accounts are active, but will do so in the months following. See our full charges and fees.